Skip to main content

Climb Bio, Inc.

CLYM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001768446

In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Climb Bio, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of CLYM: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders65280+17
Shares31.2M1.74M32.3M+2.81M (+9.5%)
Value$157.4M$6.96M$221.2M+$70.7M (+47.0%)

2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (27)

Institutions that held Climb Bio, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to CLYM in Q1 2026
InstitutionSharesValue% of portfolio
Braidwell LP1,529,675$10.5M0.35%
Vanguard Capital Management LLC1,178,659$8.07M0.00%
Silverarc Capital Management, LLC684,908$4.69M0.55%
Diadema Partners LP286,126$1.96M0.81%
Longaeva Partners L.P.217,768$1.49M0.07%
Superstring Capital Management LP199,209$1.36M0.97%
Vanguard Fiduciary Trust Co158,660$1.09M0.00%
Verdad Advisers, LP144,540$990.1K1.11%
Dimensional Fund Advisors LP104,437$714.5K0.00%
Boothbay Fund Management, LLC92,297$632.2K0.01%
Brevan Howard Capital Management LP56,624$387.9K0.00%
Squarepoint Ops LLC42,974$294.4K0.00%
HRT Financial LP37,161$254.0K0.00%
Cantor Fitzgerald, L. P.30,000$205.5K0.01%
Arrowpoint Investment Partners (Singapore) Pte. Ltd.24,590$168.4K0.24%
Charles Schwab Investment Management Inc22,051$151.0K0.00%
Fox Run Management, L.L.C.19,287$126.1K0.02%
Raymond James Financial Inc17,727$121.4K0.00%
Diametric Capital, LP11,218$76.8K0.02%
Susquehanna Portfolio Strategies, LLC11,056$75.7K0.00%
Vanguard Global Advisers, LLC10,061$68.9K0.00%
Advisory Services Network, LLC2,032$13.9K0.00%
Jones Financial Companies LLLP266$1.87K0.00%
Fortitude Family Office, LLC92$6300.00%
Russell Investments Group, Ltd.79$5410.00%
Allworth Financial LP45$3090.00%
SRS Capital Advisors, Inc.51$1100.00%

Sold out (10)

Institutions that held Climb Bio, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of CLYM in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Ameriprise Financial Inc139,529$558.1K
Two Sigma Advisers, LP124,700$498.8K
Squadron Capital Management LLC100,000$400.0K
Citizens Financial Group Inc28,168$112.7K
HSBC Holdings PLC24,744$99.2K
Prelude Capital Management, LLC19,918$79.7K
Chicago Partners Investment Group LLC10,962$55.0K
Virtu Financial LLC10,655$43.0K
Scientech Research LLC10,428$41.7K
Harbour Investments, Inc.2,000$8.00K

Not filed for Q1 2026 yet (2)

Institutions that held Climb Bio, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CLYM in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc1,340,504$5.36M
Kotler Kevin400,000$1.60M